Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

127 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma.
Kanemura H, Yokoyama T, Nakajima R, Nakamura A, Kuroda H, Kitamura Y, Shoda H, Mamesaya N, Miyata Y, Okamoto T, Okishio K, Oki M, Sakairi Y, Chen-Yoshikawa TF, Aoki T, Ohira T, Matsumoto I, Ueno K, Miyazaki T, Matsuguma H, Yokouchi H, Otani T, Ito A, Sakai K, Chiba Y, Nishio K, Yamamoto N, Okamoto I, Nakagawa K, Takeda M. Kanemura H, et al. JTO Clin Res Rep. 2024 Mar 8;5(4):100658. doi: 10.1016/j.jtocrr.2024.100658. eCollection 2024 Apr. JTO Clin Res Rep. 2024. PMID: 38651033 Free PMC article.
The Tumor Immune Microenvironment and Frameshift Neoantigen Load Determine Response to PD-L1 Blockade in Extensive-Stage SCLC.
Kanemura H, Hayashi H, Tomida S, Tanizaki J, Suzuki S, Kawanaka Y, Tsuya A, Fukuda Y, Kaneda H, Kudo K, Takahama T, Imai R, Haratani K, Chiba Y, Otani T, Ito A, Sakai K, Nishio K, Nakagawa K. Kanemura H, et al. JTO Clin Res Rep. 2022 Jul 1;3(8):100373. doi: 10.1016/j.jtocrr.2022.100373. eCollection 2022 Aug. JTO Clin Res Rep. 2022. PMID: 35941997 Free PMC article.
Severe Immune-Related Hepatitis Treated With Plasma Exchange.
Kanemura H, Hayashi H, Hagiwara S, Otani T, Haratani K, Yonesaka K, Ito A, Kudo M, Nakagawa K. Kanemura H, et al. J Thorac Oncol. 2020 Mar;15(3):e39-e42. doi: 10.1016/j.jtho.2019.11.014. J Thorac Oncol. 2020. PMID: 32093859 Free article. No abstract available.
Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
Mitani S, Kawakami H, Shiraishi O, Kanemura H, Suzuki S, Haratani K, Hayashi H, Yonesaka K, Chiba Y, Yasuda T, Nakagawa K. Mitani S, et al. Among authors: kanemura h. Esophagus. 2023 Apr;20(2):281-289. doi: 10.1007/s10388-022-00976-9. Epub 2022 Dec 9. Esophagus. 2023. PMID: 36484900
Successful treatment with atezolizumab combination chemotherapy in a patient with high-grade fetal adenocarcinoma of the lung: A case report.
Fujimoto K, Watanabe S, Yasuda Y, Date E, Kawabata Y, Kanemura H, Takahama T, Yonesaka K, Iizuka N, Takahashi KI, Kawakami O, Ozaki T, Nakagawa K. Fujimoto K, et al. Among authors: kanemura h. Thorac Cancer. 2023 Jan;14(2):214-217. doi: 10.1111/1759-7714.14768. Epub 2022 Dec 9. Thorac Cancer. 2023. PMID: 36495048 Free PMC article.
Correction: Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
Mitani S, Kawakami H, Shiraishi O, Kanemura H, Suzuki S, Haratani K, Hayashi H, Yonesaka K, Chiba Y, Yasuda T, Nakagawa K. Mitani S, et al. Among authors: kanemura h. Esophagus. 2023 Apr;20(2):290. doi: 10.1007/s10388-023-00986-1. Esophagus. 2023. PMID: 36658273 No abstract available.
127 results